US FDA Hears Competing Messages On Off-Label Communications
Executive Summary
Over the course of a two-day meeting at FDA headquarters, the agency heard from the medtech industry, which argued for expanding rights to off-label promotion, and consumer groups that worry about the possible impact on the public health. The meeting is intended to inform FDA's comprehensive review of its regulations and policies governing firms' communications about unapproved uses of approved/cleared products.
You may also be interested in...
Comments On Off-Label Communications Guidance Point Out Possible First Amendment Violations
Stakeholders argue the draft limits crucial decision-making information and infringes on manufacturers’ free speech.
Expert: Off-Label Communications Guidance Provides Clarifications, Flexibility
A draft guidance on communications of off-label uses for medical products indicates “more flexibility and understanding from FDA” says FDA compliance expert Anne Walsh.
FDA Memo Reiterates Off-Label Enforcement Policy
Pre-Trump agency memo on manufacturer communications about unapproved uses says new court rulings and studies on off-label uses and adverse reactions support restrictions; whether agency’s new leadership has the same view remains to be seen.